Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission

Retrovirology

Volumn 3, Issue , 2006, Pages

  Ramakrishnan, Rajesh ^a,b   Mehta, Roshni ^a   Sundaravaradan, Vasudha ^a   Davis, Tiffany ^a   Ahmad, Nafees ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EPITOPE; GLYCOPROTEIN GP 41; PEPTIDE DERIVATIVE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE CLUSTER; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PERINATAL PERIOD; PHYLOGENY; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; PROTEIN MOTIF; SEQUENCE ANALYSIS; VERTICAL TRANSMISSION; AMINO ACID SEQUENCE; CHEMISTRY; DISEASE TRANSMISSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PATHOGENICITY; PHYSIOLOGY; PRESCHOOL CHILD; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CHILD, PRESCHOOL; EPITOPES, T-LYMPHOCYTE; EVOLUTION, MOLECULAR; FEMALE; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PHYLOGENY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN;

EID: 33746870020     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-42     Document Type: Article

References (72)

1. Ahmad N: The vertical transmission of human immunodeficiency virus type I: molecular and biological properties of the virus. Crit Rev Clin Lab Sci 2005, 42:1-34.
2. Abrams EJ, Wiener J, Carter R, Kuhn L, Palumbo P, Nesheim S, Lee F, Vink P, Bulterys M: Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. Aids 2003, 17:867-877.
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J: Reduction of maternal-infant transmission of human immunodeficiency virus type I with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
4. Frenkel LM, Wagner LE 2nd, Demeter LM, Dewhurst S, Coombs RW, Murante BL, Reichman RC: Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type I. Clin Infect Dis 1995, 20:1321-1326.
5. Hahn T, Matala E, Chappey C, Ahmad N: Characterization of mother-infant HIV type I gag p 17 sequences associated with perinatall transmission. AIDS Res Hum Retroviruses 1999, 15:875-888.
6. Ahmad N, Baroudy BM, Baker RC, Chappey C: Genetic analysis of human immunodeficiency virus type I envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995, 69:1001-1012.
7. Sundaravaradan V, Hahn T, Ahmad N: Conservation of functional domains and limited heterogeneity of HIV-1 reverse transcriptase gene following vertical transmission. Retrovirology 2005, 2:36.
8. Wellensiek BP, Sundaravaradan V, Ramakrishnan R, Ahmad N: Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission. Retrovirology 2006, 3:21.
9. Husain M, Hahn T, Yedavalli VR, Ahmad N: Characterization of HIV type I tat sequences associated with perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:765-773.
10. Ramakrishnan R, Husain M, Holzer A, Mehta R, Sundaravaradan V, Ahmad N: Evaluations of HIV type I rev gene diversity and functional domains following perinatal transmission. AIDS Res Hum Retroviruses 2005, 21:1035-1045.
11. Yedavalli VR, Chappey C, Matala E, Ahmad N: Conservation of an intact vif gene of human immunodeficiency virus type I during maternal-fetal transmission. J Virol 1998, 72:1092-1102.
12. Yedavalli VR, Chappey C, Ahmad N: Maintenance of an intact human immunodeficiency virus type I vpr gene following mother-to-infant transmission. J Virol 1998, 72:6937-6943.
13. Yedavalli VR, Husain M, Horodner A, Ahmad N: Molecular characterization of HIV type I vpu genes from mothers and infants after perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:1089-1098.
14. Hahn T, Ramakrishnan R, Ahmad N: Evaluation of genetic diversity of human immunodeficiency virus type I NEF gene associated with vertical transmission. JBiomed Sci 2003, 10:436-450.
15. Matala E, Crandall KA, Baker RC, Ahmad N: Limited heterogeneity of HIV type I in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retrovinises 2000, 16:1481-1489.
16. Yedavalli VR, Ahmad N: Low conservation of functional domains of HIV type I vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 2001, 17:911-923.
17. Hahn T, Ahmad N: Genetic characterization of HIV type I gag p 17 matrix genes in isolates from infected mothers lacking perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:1673-1680.
18. Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
19. Boge M, Wyss S, Bonifacino JS, Thali M: A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J Biol Chem 1998, 273:15773-15778.
20. Day JR, Munk C, Guatelli JC: The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type I gp41 is required for optimal viral infectivity. J Virol 2004, 78:1069-1079.
21. Tencza SB, Miller MA, Islam K, Mietzner TA, Montelaro RC: Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-I peptide segment of human immunodeficiency virus type I transmembrane protein. J Virol 1995, 69:5199-5202.
22. Perrin C, Fenouillet E, Jones IM: Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type I envelope glycoprotein. Virology 1998, 242:338-345.
23. Johnson WE, Sauvron JM, Desrosiers RC: Conserved, N-linked carbohydrates of human immunodeficiency virus type I gp41 are largely dispensable for viral replication. J Virol 2001, 75:11426-11436.
24. Swofford DI: PAUP* Phylogenetic analysis using PArsimony and other methods vol 4 Sunderland, MA, Sinauer Associated; 1999.
25. Koulinska IN, Chaplin B, Mwakagile D, Essex M, Renjifo B: Hyper-mutation of HIV type I genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses 2003, 19:1115-1123.
26. Kuhner MK, Yamato J, Felsenstein J: Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Genetics 1995, 140:1421-1430.
27. Kuhner MK, Yamato J, Felsenstein J: Maximum likelihood estimation of population growth rates based on the coalescent. Genetics 1998, 149:429-434.
28. Nielsen R, Yang Z: Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 1998, 148:929-936.
29. Freed EO, Myers DJ, Risser R: Characterization of the fusion domain of the human immunodeficiency virus type I envelope glycoprotein gp41. Proc Natl Acad Sci USA 1990, 87:4650-4654.
30. Chen SS, Lee CN, Lee WR, McIntosh K, Lee TH: Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type I envelope transmembrane glycoprotein. J Virol 1993, 67:3615-3619.
31. Dubay JW, Roberts SJ, Brody B, Hunter E: Mutations in the leucine zipper of the human immunodeficiency virus type I transmembrane glycoprotein affect fusion and infectivity. J Virol 1992, 66:4748-4756.
32. Wild C, Dubay JW, Greenwell T, Baird T Jr, Oas TG, McDanall C, Hunter E, Matthews T: Propensity for a leucine zipper-like domain of human immunodeficiency virus type I gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994, 91:12676-12680.
33. Weng Y, Yang 4 Weiss CD: Structure-function studies of the self-assembly domain of the human immunodeficiency virus type I transmembrane protein gp41. J Virol 2000, 74:5368-5372.
34. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ: Selection for neutralization resistance of the simian/human immuno-deficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 1999, 73:5294-5300.
35. Reitter JN, Means RE, Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nat Med 1998, 4:679-684.
36. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy R, Murphy RL, Wolinsky SM, Gabuzda D: Genetic and functional analysis of full-length human immunodeficiency virus type I env genes derived from brain and blood of patients with AIDS. J Virol 2003, 77:12336-12345.
37. Salzwedel K, Johnston PB, Roberts SJ, Dubay JW, Hunter E: Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type I envelope glycoproteins. J Virol 1993, 67:5279-5288.
38. Weiss CD, White JM: Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosyl-phosphatidylinositol-anchored human immunodeficiency virus type I envelope glycoprotein. J Virol 1993, 67:7060-7066.
39. Miyauchi K, Komano J, Yokomaku Y, Sugiura W, Yamamoto N, Matsuda Z: Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type I in membrane fusion. J Virol 2005, 79:4720-4729.
40. Wyss S, Berlioz-Torrent C, Boge M, Blot G, Honing S, Benarous R, Thali M: The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type I envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]. J Virol 2001, 75:2982-2992.
41. Rapoport I, Chen YC, Cupers P, Shoelson SE, Kirchhausen T: Dileucine-based sorting signals bind to the beta chain of AP-I at a site distinct and regulated differently from the tyrosine-based motif-binding site. Embo J 1998, 17:2148-2155.
42. Piller SC, Dubay JW, Derdeyn CA, Hunter E: Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type I: effects on glycoprotein incorporation and infectivity. J Virol 2000, 74:11717-11723.
43. Tencza SB, Mietzner TA, Montelaro RC: Calmodulin-binding function of LLP segments from the HIV type I transmembrane protein is conserved among natural sequence variants. AIDS Res Hum Retroviruses 1997, 13:263-269.
44. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Mathews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41 mediated virus entry. Nat Med 1998, 4:1302-1307.
45. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR: Relative replicative fitness of human immunodeficiency virus type I mutants resistant to enfuvirtide (T-20). J Virol 2004, 78:4628-4637.
46. Poveda. E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V: Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004, 74:21-28.
47. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA: Determinants of human immunodeficiency virus type I baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004, 78:7582-7589.
48. Borkow G, Lara HH, Lapidot A: Mutations in gp41 and gp 120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate. Biochem Biophys Res Commun 2003, 312:1047-1052.
49. Ugolini S, Mondor I, Parren PW, Burton DR, Tilley SA, Klasse PJ, Sattentau QJ: Inhibition of virus attachment to CD4+target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997, 186:1287-1298.
50. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H: A potent cross-clade neutralizing hurnan monoclonal antibody against a novel epitope on gp4l of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
51. Rowland-Jones SL, Phillips RE, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, McMichael AJ: Human immunodeficiency virus variants that escape cytotoxic T-cell recognition. AIDS Res Hum Retroviruses 1992, 8:1353-1354.
52. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CR, Phillips RE Positive selection of HIV- 1 cytotoxic T lymphocyte escape variants during primary infection. Proc Nod Acad Sci USA 1997, 94:1890-1895.
53. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenber ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funchouser R, Pelto SI, Burchett SK, mcintosh K, Korber BT, Walker BD: Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334-338.
54. Geels MJ, Cornelissen M, Schuitemaker H, Anderson K, Kwa D, Maas J, Dekker JT, Baan E, Zorgdrager F, van den Burg R, van Beelen M, Lukashov W, Fu TM, Paxton WA, van der Hoek L, Dubey SA, Shiver JW, Goudsmit L. Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1 -infected individual. J Virol 2003, 77:12430-12440.
55. Wilson CC, Brown RC, Korber BT, Wilkes BM, Ruhl DJ, Sakamoto D, Kunstman K, Luzuriaga K, Hanson IC, Widmayer SM, Wiznia A, Clapp S, Ammann AJ, Koup RA, Wolinsky SM, Walker BD: Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant. J Virol 1999, 73:3975-3985.
56. Hunter E: Sgp4l, a multifunctional protein involved in HIV entry and pathogenesis. In Human Retrovirus and AIDS Edited by: Korber BHB, Foley B, Mellors J, Leitner T, Myers G, McCutchan F, Kuiken C. Los Alamos, NM: Los Alamos National Library; 1997:11155-11173.
57. Lu M, Stoller MO, Wang S, Liu J, Fagan MB, Nunberg JH: Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp4l envelope glyco- protein by alanine-scanning mutagenesis. J Virol 2001, 75: 11146-11156.
58. Epstein LG, Sharer LR. Neurological manifestations of perinatally acquired HIV-1 infection. Semin Pediatr Neural 1994, 1:50-57.
59. Kao SM, Miller ED, Su L: A leucine zipper motif in the cytoplasmic domain of gp4l is required for HIV- 1 replication and pathogenesis in vivo. Virology 2001, 289:208-217.
60. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F Baseline susceptibility of primary human immu- nodeficiency virus type 1 to entry inhibitors. J Virol 2003, 77:1610-1613.
61. Derdeyn CA, Decker JM, Sfaldanas JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E: Sensitivity of human immuno- deficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the Y3 loop of gp 120. J Virol 2000, 74:8358-8367.
62. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Nad Acad Sci USA 2002, 99:16249-16254.
63. Matala E, Hahn T, Yedavalli VR, Ahmad N: Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:1725-1735.
64. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
65. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep 1987, 36:225-230. 235-226
66. Aclachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA: Production of acquired immunodeficiency syndrome- associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291.
67. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD: Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003, 31:3497-3500.
68. Posada D, Crandall KA: Selecting models of nucleotide substitution: an application to human immunodeficiency virus 1 (HIV- 1). Mot Biol Evol 2001, 18:897-906.
69. Posada D, Crandall KA: MODELTEST: testing the model of DNA substitution. Bioinformatics 1998, 14:817-818.
70. Akaike H: A new look at the statistical model identification. IEEE Trans Autom Contrib 1974, 19:716-723.
71. Fetching the COALESCE program [http://evolution.genet ics.washington.edu/lamarc/coalesce.htm]
72. Phylogentic Analysis by Maximum Likelihood (PAML), version 3.0 [http://abacus/gene.uci.ac.uk.software/pam/.htm]